Álvaro López-Díaz

Dr. Álvaro López-Díaz

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2020 in Revista de Psiquiatría y Salud Mental
Verified
Journal Article
Closed access
MVMaría José Valdés-Florido
María José Valdés-Florido
ÁLÁlvaro López-Díaz
Álvaro López-Díaz
FPFernanda Jazmín Palermo-Zeballos
Fernanda Jazmín Palermo-Zeballos
IMIván Martínez-Molina
Iván Martínez-Molina
VMVictoria Eugenia Martín-Gil
Victoria Eugenia Martín-Gil
MRMiguel Ruiz-Veguilla
Miguel Ruiz-Veguilla

25 January 2018 in Psychiatry Investigation
Verified
Journal Article
Open access
PDF file
ÁLÁlvaro López-Díaz
Álvaro López-Díaz
ILIgnacio Lara
Ignacio Lara
GLGuillermo Lahera
Guillermo Lahera
López-Díaz Á, et al. Psychiatry Investig. 2018 Jan;15(1):94-98. https://doi.org/10.4306/pi.2018.15.1.94

18 January 2017 in Therapeutic Advances in Psychopharmacology
Verified
Journal Article
Closed access
ÁLÁlvaro López-Díaz
Álvaro López-Díaz
JFJosé Luis Fernández-González
José Luis Fernández-González
JLJosé Evaristo Luján-Jiménez
José Evaristo Luján-Jiménez
SGSara Galiano-Rus
Sara Galiano-Rus
LGLuis Gutiérrez-Rojas
Luis Gutiérrez-Rojas
The rapidly-acting antidepressant properties of ketamine are a trend topic in psychiatry. Despite its robust effects, these are ephemeral and can lead to certain adverse events. For this reason, there is still a general concern around the off-label use of ketamine in clinical practice settings. Nonetheless, for refractory depression, it should be an indication to consider. We report the case of a female patient admitted for several months due to a treatment-resistant depressive bipolar episode with chronic suicidal behaviour. After repeated intravenous ketamine infusions without remarkable side effects, the patient experienced a complete clinical recovery during the 4 weeks following hospital discharge. Unfortunately, depressive symptoms reappeared in the 5th week, and the patient was finally readmitted to hospital as a result of a suicide attempt.

21 February 2023 in The British Journal of Psychiatry
Verified
Journal Article
Open access
PDF file
MCManuel Canal-Rivero
Manuel Canal-Rivero
MRMiguel Ruiz-Veguilla
Miguel Ruiz-Veguilla
VFVictor Ortiz-García de la Foz
Victor Ortiz-García de la Foz
ÁLÁlvaro López-Díaz
Álvaro López-Díaz
NGNathalia Garrido-Torres
Nathalia Garrido-Torres
BCBenedicto Crespo-Facorro
Benedicto Crespo-Facorro
Background: Understanding the evolution of negative symptoms in first-episode psychosis (FEP) requires long-term longitudinal study designs that capture the progression of this condition and the associated brain changes.Aims: To explore the factors underlying negative symptoms and their association with long-term abnormal brain trajectories.Method: We followed up 357 people with FEP over a 10-year period. Factor analyses were conducted to explore negative symptom dimensionality. Latent growth mixture modelling (LGMM) was used to identify the latent classes. Analysis of variance (ANOVA) was conducted to investigate developmental trajectories of cortical thickness. Finally, the resulting ANOVA maps were correlated with a wide set of regional molecular profiles derived from public databases.Results: Three trajectories (stable, decreasing and increasing) were found in each of the three factors (expressivity, experiential and attention) identified by the factor analyses. Patients with an increasing trajectory in the expressivity factor showed cortical thinning in caudal middle frontal, pars triangularis, rostral middle frontal and superior frontal regions from the third to the tenth year after the onset of the psychotic disorder. The F-statistic map of cortical thickness expressivity differences was associated with a receptor density map derived from positron emission tomography data.Conclusions: Stable and decreasing were the most common trajectories. Additionally, cortical thickness abnormalities found at relatively late stages of FEP onset could be exploited as a biomarker of poor symptom outcome in the expressivity dimension. Finally, the brain areas with less density of receptors spatially overlap areas that discriminate the trajectories of the expressivity dimension.

1 November 2018 in Psychiatry Research
Verified
Journal Article
Closed access
ÁLÁlvaro López-Díaz
Álvaro López-Díaz
PLPablo Lorenzo-Herrero
Pablo Lorenzo-Herrero
ILIgnacio Lara
Ignacio Lara
JFJosé Luis Fernández-González
José Luis Fernández-González
MRMiguel Ruiz-Veguilla
Miguel Ruiz-Veguilla

6 May 2019 in European Archives of Psychiatry and Clinical Neuroscience
Verified
Journal Article
Closed access
PDF file
ÁLÁlvaro López-Díaz
Álvaro López-Díaz
JFJosé Luis Fernández-González
José Luis Fernández-González
ILIgnacio Lara
Ignacio Lara
MRMiguel Ruiz-Veguilla
Miguel Ruiz-Veguilla